Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://hamzahsohu481921.theobloggers.com/49477168/retatrutide-australia-a-potential-solution-for-obesity-treatment